CNGA2 Inhibitors
CNGA2 inhibitors are chemical compounds that selectively inhibit the function of the CNGA2 protein, a subunit of the cyclic nucleotide-gated (CNG) ion channels. CNGA2 is primarily expressed in the olfactory sensory neurons in the nasal epithelium, where it plays a critical role in the detection of odorant molecules. These ion channels are activated by cyclic nucleotides, particularly cyclic adenosine monophosphate (cAMP), which is produced in response to the binding of odorant molecules to G-protein-coupled receptors (GPCRs). Once activated, the CNG channels allow the influx of cations such as sodium and calcium into the neuron, leading to membrane depolarization and the generation of an electrical signal that is transmitted to the brain for odor perception. Inhibitors of CNGA2 block this ion flow, thereby modulating the olfactory signaling pathway.
The specificity of CNGA2 inhibitors is important because CNG channels consist of various subunits, each contributing to different physiological functions. CNGA2 is distinct from other CNG channel subunits due to its primary localization in olfactory neurons and its role in sensory transduction. By inhibiting CNGA2, these compounds help elucidate the functional aspects of olfactory signal processing and provide insights into the biophysical properties of CNG channels. These inhibitors are valuable tools in research focused on understanding the molecular mechanisms of olfaction, as well as in studying the broader roles of cyclic nucleotide signaling in sensory physiology. The inhibition of CNGA2 provides a targeted approach to dissecting the contributions of specific ion channels in cellular excitability and signal propagation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, is also reported to inhibit CNG channels and thus can inhibit CNGA2 by reducing the open probability of the channel, effectively decreasing its ion conductance. | ||||||
Trifluoperazine Dihydrochloride | 440-17-5 | sc-201498 sc-201498A | 1 g 5 g | $56.00 $99.00 | 9 | |
Trifluoperazine, a phenothiazine derivative, has been shown to inhibit CNG channels, which implies that it can inhibit CNGA2 by altering the channel conformation, leading to a reduced ion flow through the channel. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride, though primarily a diuretic affecting sodium channels, can inhibit CNG channels like CNGA2 by reducing the sensitivity of the channel to cyclic nucleotides, which are essential for their activation. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
Quinidine has been reported to inhibit CNG channels, and therefore can inhibit CNGA2 by blocking the ion-conducting pore of the channel, preventing ion permeation. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Chlorpromazine, an antipsychotic medication, can inhibit CNG channels, suggesting it could inhibit CNGA2 by altering channel gating and thereby decreasing ion flow. | ||||||
Tetracaine | 94-24-6 | sc-255645 sc-255645A sc-255645B sc-255645C sc-255645D sc-255645E | 5 g 25 g 100 g 500 g 1 kg 5 kg | $66.00 $309.00 $500.00 $1000.00 $1503.00 $5000.00 | ||
Tetracaine, a local anesthetic, can inhibit CNG channels, thus it may inhibit CNGA2 by binding to the channel in a manner that reduces its open probability or directly occludes the ion-conducting pathway. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $50.00 $128.00 | ||
Lidocaine, another local anesthetic, is known to inhibit CNG channels and can therefore inhibit CNGA2 by diminishing the channel's ability to conduct ions, possibly by binding to sites within the channel pore or altering its gating mechanisms. | ||||||
Procaine | 59-46-1 | sc-296134 sc-296134A sc-296134B sc-296134C | 25 g 50 g 500 g 1 kg | $108.00 $189.00 $399.00 $616.00 | 1 | |
Procaine is a local anesthetic that can inhibit CNG channels. This suggests that it can inhibit CNGA2 by decreasing the channel's ion conductance through a mechanism similar to other local anesthetics, such as altering the gating or blocking the pore. | ||||||
Psoralen | 66-97-7 | sc-205965 sc-205965A | 25 mg 100 mg | $101.00 $315.00 | 1 | |
Psoralen, a naturally occurring compound, has been found to inhibit CNG channels, potentially by binding to the channel proteins and altering their conformation, which in turn could inhibit CNGA2 by preventing its normal gating and ion conduction. | ||||||